meta
|
evidence
COVID-19
Living systematic review and meta-analysis
IFN beta-1b
***** adjuvant therapies
anti-inflammatoty and immuno-therapy
Immunostimulants drugs
interferon
IFN beta-1a
IFN beta-1b
IFN gamma
inhaled interferon
interferon / TFF2
peginterferon
PNB001
***** antiandrogenic
***** antiviral and associated therapy
***** control
***** Drugs for acid related disorders
***** miscellaneous
***** Oral antidiabetic drugs
***** Renin-angiotensin-system-acting agents
***** vaccines
***** Vitamins
secondary prevention
COVID 19 hospitalized
COVID 19 all comers
COVID-19 mild to moderate
COVID-19 severe or critically
COVID 19 outpatients
COVID-19 (hospitalized or not)
COVID-19 prophylaxis (children)
COVID-19 prophylaxis (excluding children)
infections other than COVID-19
Long COVID-19
preventing respiratory virus transmission
secondary prevention
Meta-analysis results for all treatments
Treatment relative effect with 95% CI; and degree of certainty (adaptated from GRADE).
method
Treament
Trials
Summary
Endpoints
deaths
clinical improvement (time to event analysis only)
hospital discharge
mechanical ventilation
ICU admission
superinfection
deaths
deaths
clinical improvement (time to event analysis only)
hospital discharge
mechanical ventilation
ICU admission
superinfection
core analysis (OBS if no RCT)
RCTs only
all (RCT+OBS)
core analysis (OBS if no RCT)
core analysis (OBS if no RCT)
RCTs only
all (RCT+OBS)
clinical deterioration
clinical improvement
deaths
viral clearance